214 related articles for article (PubMed ID: 25490180)
21. Autologous stem-cell transplantation for non-Hodgkin's lymphomas: the role of graft purging and radiotherapy posttransplantation--results of a retrospective analysis on 120 patients autografted in a single institution.
Fouillard L; Laporte JP; Labopin M; Lesage S; Isnard F; Douay L; Lopez M; Aoudjhane M; Zunic P; Cheron N; Stachowiak J; Lemonnier MP; Andreu G; Belkacemi Y; Noël-Walter MP; Morel P; Fenaux P; Jouet JP; Bauters F; Najman A; Gorin NC
J Clin Oncol; 1998 Aug; 16(8):2803-16. PubMed ID: 9704733
[TBL] [Abstract][Full Text] [Related]
22. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
23. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
Flowers CR; Costa LJ; Pasquini MC; Le-Rademacher J; Lill M; Shore TB; Vaughan W; Craig M; Freytes CO; Shea TC; Horwitz ME; Fay JW; Mineishi S; Rondelli D; Mason J; Braunschweig I; Ai W; Yeh RF; Rodriguez TE; Flinn I; Comeau T; Yeager AM; Pulsipher MA; Bence-Bruckler I; Laneuville P; Bierman P; Chen AI; Kato K; Wang Y; Xu C; Smith AJ; Waller EK
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1197-1205. PubMed ID: 27040394
[TBL] [Abstract][Full Text] [Related]
25. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
26. [Autologous transplant with BEAM protocol in lymphoma].
Caballero D; Rubio V; Rifon J; Heras I; García-Sanz R; Vidriales B; Pérez-Simón JA; del Cañizo C; González M; León A; Jean-Paul E; Rocha E; Vicente V; San Miguel JF
Sangre (Barc); 1997 Apr; 42 Suppl 1():46-9. PubMed ID: 9381303
[No Abstract] [Full Text] [Related]
27. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy.
Jantunen E; Kuittinen T; Nousiainen T
Leuk Lymphoma; 2003 Jul; 44(7):1151-8. PubMed ID: 12916867
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome.
Armand P; Kim HT; Ho VT; Cutler CS; Koreth J; Antin JH; LaCasce AS; Jacobsen ED; Fisher DC; Brown JR; Canellos GP; Freedman AS; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2008 Apr; 14(4):418-25. PubMed ID: 18342784
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant?
Seyfarth B; Kuse R; Sonnen R; Glass B; Schmitz N; Dreger P
Ann Hematol; 2001 Jul; 80(7):398-405. PubMed ID: 11529465
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease.
Martín A; Fernández-Jiménez MC; Caballero MD; Canales MA; Pérez-Simón JA; García de Bustos J; Vázquez L; Hernández-Navarro F; San Miguel JF
Br J Haematol; 2001 Apr; 113(1):161-71. PubMed ID: 11328296
[TBL] [Abstract][Full Text] [Related]
31. Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial.
Deconinck E; Lamy T; Foussard C; Gaillard F; Delwail V; Colombat P; Casassus P; Lemevel A; Brion A; Milpied N
Br J Haematol; 2000 Jun; 109(4):736-42. PubMed ID: 10929023
[TBL] [Abstract][Full Text] [Related]
32. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Caballero MD; Pérez-Simón JA; Iriondo A; Lahuerta JJ; Sierra J; Marín J; Gandarillas M; Arranz R; Zuazu J; Rubio V; Fernández de Sevilla A; Carreras E; García-Conde J; García-Laraña J; Grande C; Sureda A; Vidal MJ; Rifón J; Pérez-Equiza C; Varela R; Moraleda JM; García Ruíz JC; Albó C; Cabrera R; San Miguel JF; Conde E
Ann Oncol; 2003 Jan; 14(1):140-51. PubMed ID: 12488306
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome.
Popat U; Przepiork D; Champlin R; Pugh W; Amin K; Mehra R; Rodriguez J; Giralt S; Romaguera J; Rodriguez A; Preti A; Andersson B; Khouri I; Claxton D; de Lima M; Donato M; Anderlini P; Gajewski J; Cabanillas F; van Besien K
J Clin Oncol; 1998 Jan; 16(1):63-9. PubMed ID: 9440724
[TBL] [Abstract][Full Text] [Related]
34. Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.
Krishnan AY; Palmer J; Nademanee AP; Chen R; Popplewell LL; Tsai NC; Sanchez JF; Simpson J; Spielberger R; Yamauchi D; Forman SJ
Biol Blood Marrow Transplant; 2017 Jun; 23(6):922-929. PubMed ID: 28267593
[TBL] [Abstract][Full Text] [Related]
35. A prospective study of intensive induction therapy with high-dose consolidation in patients with aggressive non-Hodgkin's lymphoma and two or three adverse prognostic factors.
Dumontet C; Thieblemont C; Espinouse D; Bouafia F; Hequet O; Salles G; Coiffier B
Leukemia; 2000 Dec; 14(12):2159-65. PubMed ID: 11187906
[TBL] [Abstract][Full Text] [Related]
36. BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients.
Faulkner RD; Craddock C; Byrne JL; Mahendra P; Haynes AP; Prentice HG; Potter M; Pagliuca A; Ho A; Devereux S; McQuaker G; Mufti G; Yin JL; Russell NH
Blood; 2004 Jan; 103(2):428-34. PubMed ID: 12969983
[TBL] [Abstract][Full Text] [Related]
37. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation.
Salloum E; Jillella AP; Nadkarni R; Seropian S; Hu GL; D'Andrea E; Zelterman D; Cooper DL
Cancer; 1998 Apr; 82(8):1506-12. PubMed ID: 9554528
[TBL] [Abstract][Full Text] [Related]
38. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside, and melphalan (BEAM) followed by autologous bone marrow transplantation: toxicity and antitumor activity in 26 patients with poor-risk malignancies.
Gaspard MH; Maraninchi D; Stoppa AM; Gastaut JA; Michel G; Tubiana N; Blaise D; Novakovitch G; Rossi JF; Weiller PJ
Cancer Chemother Pharmacol; 1988; 22(3):256-62. PubMed ID: 3044633
[TBL] [Abstract][Full Text] [Related]
39. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial.
Linch DC; Winfield D; Goldstone AH; Moir D; Hancock B; McMillan A; Chopra R; Milligan D; Hudson GV
Lancet; 1993 Apr; 341(8852):1051-4. PubMed ID: 8096958
[TBL] [Abstract][Full Text] [Related]
40. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas.
Colombat P; Biron P; Laporte JP; Cahn JY; Herve P; Gorin NC; Lamagnere JP; Philip T
Eur J Cancer; 1990; 26(7):858. PubMed ID: 2145921
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]